Paper Details

  1. Home
  2. Paper Details

Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.

Author: ChenChangzheng, GommollCarl P, GreenbergWilliam M, MontgomeryStuart A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Levomilnacipran extended-release (ER) is efficacious for major depressive disorder (MDD) across a wide range of patients. In pooled data from 5 phase II/III studies, levomilnacipran ER showed significant improvements in MADRS scores, response rates, and remission rates compared to placebo. These effects were consistent across subgroups based on sex, age, MDD duration, and symptom severity.
Paper Details　
Original Abstract of the Article :
INTRODUCTION/OBJECTIVE: Post hoc analyses were conducted to evaluate the efficacy of levomilnacipran extended-release (ER) in subgroups of patients with major depressive disorder (MDD). METHODS: Data were pooled from 5 completed Phase II/III studies. Patients were categorized by sex, age, MDD durat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411644/

データ提供：米国国立医学図書館（NLM）

Levomilnacipran Extended-Release: A Promising Treatment for Major Depressive Disorder

The study delves into the realm of major depressive disorder (MDD), exploring the efficacy of levomilnacipran extended-release (ER). The research meticulously analyzed data from five double-blind, placebo-controlled trials, encompassing a diverse patient population with varying characteristics such as age, sex, and MDD history. This comprehensive approach aimed to determine whether levomilnacipran ER consistently demonstrated therapeutic benefit across different subgroups. The research suggests that levomilnacipran ER shows significant efficacy across a wide range of MDD patients, including individuals with varying symptom severity and treatment history.

A Beacon of Hope for Diverse MDD Patients

The results reveal statistically significant improvements in MADRS scores and response rates for levomilnacipran ER compared to placebo. These findings hold promise for improving the lives of individuals struggling with MDD. The fact that efficacy was observed across various subgroups, including those with high baseline MADRS scores, strengthens the potential of this treatment option.

Finding Relief from Depression: A Holistic Approach

The study suggests that levomilnacipran ER might be an effective treatment option for a broad spectrum of MDD patients. However, it is essential to remember that treatment should be tailored to individual needs and may involve a combination of therapies. This research encourages individuals struggling with MDD to seek professional help and explore available treatment options.

Dr.Camel's Conclusion

Just as a desert oasis provides respite to weary travelers, this research offers a glimmer of hope for individuals battling MDD. This study suggests that levomilnacipran ER could be a valuable tool in the fight against this debilitating condition. By understanding the nuances of this treatment, we can strive to provide compassionate and effective care for those in need.

Date :
  1. Date Completed 2015-09-15
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24902007

DOI: Digital Object Identifier

PMC4411644

Related Literature

Article Analysis
・Effects of levomilnacipran
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.